NICE seeks comments on cost-sharing schemes
This article was originally published in Scrip
The National Institute for health and Clinical Excellence (NICE) is proposing changes to the way it takes flexible pricing schemes and patient access programmes into account as it evaluates health technologies for the national health service in England and Wales.
You may also be interested in...
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.